Press Releases March 30, 2026 08:00 PM

Manhattan Bridge Capital, Inc. Announces Payment of Quarterly Dividend

Manhattan Bridge Capital declares quarterly cash dividend to shareholders

By Sofia Navarro
Share
Twitter Reddit Facebook LinkedIn
LOAN

Manhattan Bridge Capital, Inc. announced a quarterly dividend of $0.11 per share, to be paid to shareholders of record on April 8, 2026, with the payment set for April 15, 2026, reflecting the company's commitment to returning value to its investors.

Manhattan Bridge Capital, Inc. Announces Payment of Quarterly Dividend
LOAN
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Declared quarterly cash dividend of $0.11 per share.
  • Dividend record date set for April 8, 2026, with payment on April 15, 2026.
  • Demonstrates company’s ongoing shareholder value strategy and financial stability.

GREAT NECK, N.Y., March 31, 2026 (GLOBE NEWSWIRE) -- Manhattan Bridge Capital, Inc. (NASDAQ: LOAN) announced today that, in accordance with the board approved dividend declared on February 10, 2026, a cash dividend of $0.11 per share will be paid to all shareholders of record on April 8, 2026. The dividend will be paid on April 15, 2026.


Risks

  • Payment of dividends depends on sufficient earnings, which may fluctuate, impacting future dividend payments.
  • Economic conditions and interest rate changes could affect the company's lending business and dividend sustainability.
  • Market conditions may influence investor sentiment despite the dividend announcement, creating potential volatility.

More from Press Releases

Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026 ROMA Green Finance Establishes Dedicated Artificial Intelligence and High-Performance Computing Infrastructure Investment Vertical Jun 12, 2026